Navigation Links
ARCA biopharma Appoints James Carr as Vice President of Marketing
Date:8/1/2008

BROOMFIELD, Colo., Aug. 1 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed James Carr, PharmD, as vice president of marketing. In this newly created position, Mr. Carr will define and execute marketing programs to support the company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator in late-stage development for heart failure.

"Jim brings senior pharmaceutical industry experience and a deep knowledge of the heart failure market, which will be of significant value to ARCA as the company prepares to commercialize the first personalized cardiovascular medicine," said Richard B. Brewer, president and chief executive officer of ARCA. "We are pleased to be able to attract talented professionals to help us accelerate the company's growth and success, and welcome Jim to the ARCA team."

Mr. Carr joins ARCA from Anesiva, Inc., where he served as vice president of marketing for pain management products since 2004. In this role, he was responsible for leading the development and launch teams for Zingo(TM), a rapid acting topical anesthetic. Prior to Anesiva, Mr. Carr was with GlaxoSmithKline (GSK) for eight years, where he led the launch for the post-myocardial infarction indication for Coreg(R) (carvedilol), a leading treatment for heart failure. During his tenure at GSK, Carr held management positions in professional relations, managed care marketing, medical education, advisory boards, publications, and lifecycle management.

Prior to joining the pharmaceutical industry, Mr. Carr was a researcher at the University at Buffalo School of Pharmacy. He earned a Doctor of Pharmacy degree from the University of Minnesota and conducted post-graduate work in the area of polymorphic drug metabolism of beta-blockers, also at the University of Minnesota.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product, Gencaro(TM) (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to Gencaro. The company plans to file a New Drug Application with the U.S. Food and Drug Administration during the summer of 2008 for approval of Gencaro for the treatment of heart failure. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. If approved, Gencaro could become the first genetically personalized cardiovascular therapy. For more information please visit http://www.arcabiopharma.com.


'/>"/>
SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):